WHO Pharmaceuticals Newsletter 2004, No. 06
(2004; 13 pages) Ver el documento en el formato PDF
Índice de contenido
Abrir esta carpeta y ver su contenidoREGULATORY MATTERS
Cerrar esta carpetaSAFETY OF MEDICINES
Ver el documentoCHOLINESTERASE INHIBITORS - Reports of cardiac arrhythmias
Ver el documentoCYCLOOXYGENASE-2 INHIBITORS - Plans to review all medicines in this class
Ver el documentoETHINYLESTRADIOL/CYPROTERONE - Increased risk of thrombosis
Ver el documentoHERBAL MEDICINES - Cardiovascular ADRs reported to Health Canada
Ver el documentoINFLUENZA VIRUS VACCINE - Interactions with drugs
Ver el documentoMEDROXY PROGESTERONE - Effect on bone mineral density
Ver el documentoPAMIDRONATE DISODIUM, ZOLEDRONIC ACID - Spontaneous reports of osteonecrosis of the jaw
Ver el documentoSELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs) - ADRAC reviews use in children and adolescents
Ver el documentoTERBINAFINE - Reports of blood dyscrasias
Ver el documentoTRICYCLIC ANTIDEPRESSANTS - Overdose risk
Ver el documentoFEATURE
 

CHOLINESTERASE INHIBITORS - Reports of cardiac arrhythmias

Australia. The increased cholinergic activity seen with cholinesterase inhibitors may have vagal effects on heart rate (HR), including bradycardia. The Australian Adverse Drug Reactions Advisory Committee (ADRAC) has received a number of reports of cardiac arrhythmias in association with the cholinesterase inhibitors donepezil (Aricept), rivastigmine (Exelon) and galantamine (Reminyl), which are increasingly used for Alzheimer's disease (see table).

ADRAC reports of cholinesterase inhibitor-associated arrhythmia

 

Donepezil

Rivastigmine

Galantamine

Bradycardia

14

7

6

Bundle branch block

1

-

1

AV block

5

-

1

Syncope

10

8

4

Unspecified arrhythmia

2

-

1

MI/cardiac arrest

7

1

-

Reference:

Australian Adverse Drug Reactions Bulletin, Vol. 23, No.5, October 2004. Available on the Internet at www.tga.gov.au

Ir a la sección anterior Ir a la siguiente sección
 

Última actualización: le 3 mayo 2013